Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04647643 · ClinicalTrials.gov registry record

Real-World Safety Analysis of Paclitaxel Devices Used for the Treatment of Peripheral Arterial Disease

A clinical trial, sponsored by Lahey Clinic.

Completed
Registry status
8,000
Enrollment target

NCT04647643 is a clinical trial that has completed, run by Lahey Clinic. The registered enrollment target is 8,000 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04647643 has completed, sponsored by Lahey Clinic.

COMPLETED
Registry status
8,000 participants
Enrollment target

Study Summary

Treatment with paclitaxel-based endovascular devices (PED) has become a common treatment option for patients with peripheral artery disease (PAD) involving the femoral-popliteal artery. However, an aggregate level meta-analysis identified an association between the use of PED and increased all-cause mortality at both two and five-year follow-up intervals, though there are significant limitations of these analyses. Exploration of real-world data has been suggested as a means to further investigate the safety of PED. The current study explores the association of PED and mortality in real-world data using U.S. commercial claims from the FAIR Health data warehouse.

Interventions

  • DRUG Paclitaxel

Trial Details

FieldValue
Enrollment Target 8,000 participants
Start Date 2020-11-20
Est. Completion 2021-12-31

Sponsor

Lahey Clinic

43 total trials

What the Registry Record Tells You About NCT04647643

The ClinicalTrials.gov registry entry for NCT04647643 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 8,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lahey Clinic, which has 43 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Paclitaxel is the first listed.

NCT04647643 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04647643 about?

NCT04647643 is a clinical study titled "Real-World Safety Analysis of Paclitaxel Devices Used for the Treatment of Peripheral Arterial Disease". Treatment with paclitaxel-based endovascular devices (PED) has become a common treatment option for patients with peripheral artery disease (PAD) involving the femoral-popliteal artery. However, an aggregate level meta-analysis identified an association between the use of PED and increased all-cause...

What is the current status of trial NCT04647643?

This trial is currently completed. The enrollment target is 8,000 participants. The study started on 2020-11-20. Estimated completion is 2021-12-31.

What interventions are being tested in trial NCT04647643?

The interventions under investigation include: Paclitaxel (DRUG).

Who is sponsoring clinical trial NCT04647643?

This trial is sponsored by Lahey Clinic, which has 43 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.